Advertisement

Topics

Rapamycin Holdings, Inc. Company Profile

00:55 EDT 21st June 2018 | BioPortfolio

Rapamycin Holdings holds the exclusive licenses for Rapamycin-related research discoveries made at the University of Texas Health Science Center San Antonio. The company is leveraging a platform of Rapamycin-related discoveries applicable to the veterinary and human markets which could have dramatic implications in improving an individual's health span and in fighting age-related medical conditions.


News Articles [442 Associated News Articles listed on BioPortfolio]

Rapamycin Holdings Plans Tests of Old Immune Drug in Prostate Cancer

San Antonio — Executives at Rapamycin Holdings believe a decades-old drug used to prevent organ transplant rejection could find a new use as a treatment for prostate cancer, and hope to  begin...

Selecta Biosciences Announces FDA Acceptance of IND Application for LMB-100 and SVP-Rapamycin Com...

SVP-Rapamycin is Selecta’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology.

Topical Rapamycin Effective for TSC-Related Facial Angiofibromas

FRIDAY, June 8, 2018 -- Topical rapamycin seems effective for tuberous sclerosis complex (TSC)-related facial angiofibromas, according to a study published online May 23 in JAMA Dermatology. Mary Kay ...

Is topical rapamycin effective, safe to treat facial lesions?

(JAMA Network) Facial angiofibromas are disfiguring growths and these lesions occur in most people with tuberous sclerosis complex, a genetic disorder where growths can appear throughout the body. Cu...

Rapamycin lotion reduces facial tumors caused by tuberous sclerosis, UTHealth reports

(University of Texas Health Science Center at Houston) Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors at The University of Texas Health...

Synergistic antitumour effects of rapamycin and oncolytic reovirus

Decades-old immunosuppressant drug rapamycin could extend life

Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapi...

PubMed Articles [138 Associated PubMed Articles listed on BioPortfolio]

Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.

The use of rapamycin to extend lifespan and delay age-related disease in mice is well-established despite its potential to impair glucose metabolism which is driven partially due to increased hepatic ...

Integrin Alpha V Beta 3 Targeted Dendrimer-Rapamycin Conjugate Reduces Fibroblast-Mediated Prostate Tumor Progression and Metastasis.

Therapeutic strategies targeting both cancer cells and associated cells in the tumor microenvironment offer significant promise in cancer therapy. We previously reported that generation 5 (G5) dendrim...

Rapamycin relieves anxious emotion and synaptic plasticity deficits induced by hindlimb unloading in mice.

This study examined whether increasing autophagy could improve cognitive deficits in hindlimb unloaded (HU) mice, which was used as an animal model of synaptic plasticity impairment. Male C57BL/6 mice...

Rapamycin-insensitive mechanistic target of rapamycin regulates basal and resistance exercise-induced muscle protein synthesis.

We investigated whether rapamycin-insensitive mechanistic target of rapamycin (mTOR) signaling plays a role in regulating resistance exercise-induced muscle protein synthesis. We used a rodent model o...

Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation.

The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.

Clinical Trials [111 Associated Clinical Trials listed on BioPortfolio]

Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)

The purpose of this study is to evaluate whether adding estradiol to rapamycin better prevents coronary artery reblockage after drug-eluting stent implantation.

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is det...

Rapamycin in Relapsed Acute Lymphoblastic Leukemia

This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used a...

Rapamycin in Advanced Cancers

The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of r...

Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)

The purpose of this study is to evaluate the efficacy of 3 different rapamycin-eluting-stent platforms to reduce coronary artery reblockage after stent implantation

Companies [442 Associated Companies listed on BioPortfolio]

Rapamycin Holdings, Inc.

Rapamycin Holdings holds the exclusive licenses for Rapamycin-related research discoveries made at the University of Texas Health Science Center San Antonio. The company is levera...

Integra Holdings

Founded by Yissum, Integra Holdings is a unique venture fund, focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in the...

Oncotarget

Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such...

Sabre Holdings

Sabre Holdings connects people with the world's greatest travel possibilities by retailing travel products and providing distribution and technology solutions for the travel indus...

HealthTech Holdings, Inc.

HealthTech Holdings, Inc. is a health information technology holding-company, with portfolio companies including HMS, MEDHOST and Sentry Healthcare Services, Inc. HealthTec...

More Information about "Rapamycin Holdings, Inc." on BioPortfolio

We have published hundreds of Rapamycin Holdings, Inc. news stories on BioPortfolio along with dozens of Rapamycin Holdings, Inc. Clinical Trials and PubMed Articles about Rapamycin Holdings, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Rapamycin Holdings, Inc. Companies in our database. You can also find out about relevant Rapamycin Holdings, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record